Key statistics
On Tuesday, Acumen Pharmaceuticals Inc (ABOS:NSQ) closed at 2.36, 30.38% above the 52 week low of 1.81 set on Nov 10, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.40 |
---|---|
High | 2.43 |
Low | 2.33 |
Bid | 2.28 |
Offer | 2.60 |
Previous close | 2.38 |
Average volume | 152.45k |
---|---|
Shares outstanding | 60.08m |
Free float | 53.33m |
P/E (TTM) | -- |
Market cap | 141.79m USD |
EPS (TTM) | -1.11 USD |
Data delayed at least 15 minutes, as of Oct 08 2024 21:00 BST.
More ▼
Announcements
- Acumen Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference
- Acumen Pharmaceuticals Extends Collaboration with Lonza to Add Drug Product Manufacturing of Sabirnetug for Early Alzheimer’s Disease
- Acumen Pharmaceuticals to Host Virtual R&D Day on Oct. 2, 2024
- Acumen Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investor Conference
- Acumen Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business Highlights
- Acumen Pharmaceuticals to Report Second Quarter Results on August 13, 2024
- Acumen Pharmaceuticals Announces First Subject Dosed in Phase 1 Study of Subcutaneous Sabirnetug (ACU193) for Early Alzheimer’s Disease
- Acumen Pharmaceuticals Presents Patient Experience and Biomarker Data from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association International Conference (AAIC®) 2024
- Acumen Pharmaceuticals to Present Patient Experience and Biomarker Insights from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association International Conference (AAIC®) 2024
- Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights
More ▼